Four trends in Health Technology Assessment
We are deeply passionate about the work we do for our clients. We have selected four trends in the areas of HTA for you to discover in more detail.
EMEA MedTech
Be ready for the paradigm shift within MedTech HTA!
At NHTA we have a strong team with extensive experience within MedTech HEOR and Market Access. We are your optimal partner for market access support from strategy to implementation.
Orphan Drugs & Rare Diseases
We have extensive expertise within Orphan drugs and rare diseases HTA support.
We are your partner for pragmatic and manageable market access solutions for Orphan Drugs and Rare Diseases, such as Managed Entry Agreements and supportive Real World Evidence.
Patient-Centered Research
We have extensive expertise within Patient-Centered Research.
We are your partner for specialized support for any patient-centered need, from patient, clinician, and caregiver outcomes, utilities and preferences, adherence and other customized prospective observational study needs.
Real World Evidence
Evidence of benefits and risks.
In addition to clinical trial data, key stakeholders often request evidence of benefits and risks in a real-world setting. Real-world evidence can be valuable to support your market access position and product uptake.
National Hospital Medication Register
Sygehusmedicinregistret (SMR)
A new registry about hospital drug gives possibilities that have not been possible before. With National Hospital Medication Register it is possible to connect hospital drugs and patients.